Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Sanofi to Acquire UK Vaccine Developer Vicebio for Up to $1.6 Billion, Expanding Respiratory Pipeline

by Team Lumida
July 22, 2025
in Markets
Reading Time: 3 mins read
A A
0
Sanofi to Acquire UK Vaccine Developer Vicebio for Up to $1.6 Billion, Expanding Respiratory Pipeline
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  1. Strategic Acquisition: Sanofi will acquire privately held Vicebio for up to $1.6 billion*$1.15 billion upfront and up to $450 million in milestone payments.
  2. Pipeline Expansion: The deal adds early-stage vaccine candidates for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to Sanofi’s pipeline, strengthening its position in respiratory vaccines.
  3. Technology Boost: Sanofi gains access to Vicebio’s molecular clamp technology, designed to enhance immune response to viral proteins.
  4. Financial Impact: The acquisition is expected to close in Q4 2025 and will not significantly affect Sanofi’s full-year guidance.
  5. Industry Context: The move reflects ongoing consolidation and investment in vaccine innovation, as major pharma companies seek to bolster their infectious disease portfolios.

What Happened?

Sanofi announced a deal to buy UK-based vaccine developer Vicebio, aiming to expand its respiratory vaccine offerings and leverage new technology for improved vaccine design. The acquisition includes significant upfront and milestone payments, and brings two promising early-stage candidates into Sanofi’s pipeline.


Why It Matters?

The deal underscores Sanofi’s commitment to growing its vaccine business and staying competitive in the respiratory disease space, an area of heightened focus post-pandemic. Access to Vicebio’s technology could accelerate Sanofi’s R&D and improve the efficacy of future vaccines.


What’s Next?

The acquisition is expected to close in the fourth quarter, pending regulatory approvals. Investors will watch for updates on the progress of Vicebio’s vaccine candidates and integration of its technology into Sanofi’s broader pipeline.

Source
Previous Post

Domino’s Pizza Revenue Rises on Strong Same-Store Sales, But Profit Falls on China Charge

Next Post

China Nears Oil Demand Peak as Domestic Output and EV Push Weaken U.S. Leverage

Recommended For You

BlackRock Triples Its Equity Overweight to 3% and Broadens AI Bets in Its $300 Billion Model Portfolios, Pulling About $4.4 Billion From Its Treasury ETF

by Team Lumida
41 minutes ago
Is BlackRock the New Leader in Alternative Investments?

BlackRock lifted its equity overweight to 3% from 1% and broadened AI exposure in its $300 billion model portfolios, driving billions in ETF flows.

Read more

Nasdaq-100 Futures Drop 0.77% and SK Hynix Sinks 5.6% as Markets Brace for Nvidia’s First Post-Huang Earnings and Anthropic’s IPO

by Team Lumida
9 hours ago
AI Bulls Trample Bond Market Warnings — S&P 500 Breaks 7,800 as Tech Rally Defies Elevated Yields, Fed Uncertainty, Global Tightening

US stock futures slipped and Asian chipmakers slid as investors braced for Nvidia's earnings and Anthropic's roughly $1.4 trillion IPO.

Read more

Nvidia’s 2031 Bond Yield Rises to 5.717% After Huang’s Exit, With $36 Billion of Neocloud Backstops Now Under Scrutiny

by Team Lumida
3 days ago

Nvidia’s 4.5% bond due 2031 yielded 5.717% on Friday, and analysts are questioning the company’s role in backing AI infrastructure after Jensen Huang’s exit.

Read more

S&P 500 Falls 0.4% and Nasdaq 0.91% on Friday as Nvidia Slides, but the Major Averages Notch Their Best Week Since August

by Team Lumida
3 days ago

The S&P 500 fell 0.4% and the Nasdaq 0.91% on Friday as Nvidia slid, but the major averages still scored their best week since August.

Read more

AI Borrowers Now Account for Almost Half of Long-Dated US Investment-Grade Issuance, With Hyperscaler Bond Sales Seen Near $250 Billion

by Team Lumida
4 days ago

AI-related borrowers now account for almost half of long-dated US investment-grade issuance, PIMCO said, urging credit diversifiers.

Read more

Nasdaq-100 Futures Slide 0.9% as Nvidia Falls More Than 8% After Hours, Leaving the Stock Down About 30% From Its Oct. 6 High

by Team Lumida
4 days ago

Nasdaq-100 futures fell 0.9% after Nvidia dropped more than 8% after hours on reports its board is preparing to oust CEO Jensen Huang.

Read more

CoreWeave Earnings Revive AI Outlook—168% Revenue Growth, FY Guidance Raised to $13-13.3B; Anthropic IPO Valuation Rebounds to $1.5T+; Nasdaq 100 Futures +1.5%; Bitcoin Steady $74K

by Team Lumida
5 days ago

CoreWeave Q3 revenue +168% YoY, net loss widened to $709M ($1.27/share) on higher interest costs. Raised FY2026 revenue guidance $13-13.3B. CRWV +10% premarket; AI infrastructure rally: IREN +6%,...

Read more

Gold Claws Back Toward $4,060 After a 2.6% Drop on Hot US CPI, Holding $4,000 as Traders Fully Price a December Fed Hike

by Team Lumida
5 days ago

Gold rose about 0.7% to $4,061.67 an ounce after a 2.6% slide on hot US inflation, holding $4,000 as traders fully price a December Fed hike.

Read more

SEC Penalties Sink to $1.1 Billion, the Lowest Since the 2008 Crisis, on 348 Enforcement Actions as Warren Readies Scrutiny of the Atkins SEC

by Team Lumida
5 days ago

The SEC obtained $1.1 billion in penalties last fiscal year, its lowest since 2008, on 348 actions as Democrats prepare to scrutinize its record.

Read more

Nasdaq-100 Futures Jump 1.43% After Nvidia’s 5.5% Slide and a Hot CPI Knocked the S&P 500 Down 0.38%, With December Hike Odds Near 90%

by Team Lumida
5 days ago

Stock futures rebounded early Wednesday after Nvidia’s slide and a hot October CPI pulled the S&P 500 down 0.38%, with December hike odds near 90%.

Read more
Next Post
China’s Financial Overhaul: Xi’s Strategy to Rebalance $9.1 Trillion Debt Crisis

China Nears Oil Demand Peak as Domestic Output and EV Push Weaken U.S. Leverage

AstraZeneca to Invest $50 Billion in U.S. Manufacturing and R&D by 2030 Amid Tariff Threats

AstraZeneca to Invest $50 Billion in U.S. Manufacturing and R&D by 2030 Amid Tariff Threats

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Private Credit Funds Pivot to Riskier Bets Amid Margin Squeeze

Apollo Moves to Contain Reputational Risk After DOJ Epstein Files Name CEO Marc Rowan

February 19, 2026
Will China’s Stimulus Ignite a Semiconductor Comeback?

Will China’s Stimulus Ignite a Semiconductor Comeback?

October 7, 2024
Morgan Stanley Q2 2024 Earnings Summary

Morgan Stanley Cuts 2,500 Jobs Despite Record Year

March 5, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018